ASCO GU 2022 Updates: Antibody-Drug Conjugates

Findings from a retrospective analysis highlight no significant differences in metastasis-free survival in patients with muscle-invasive bladder cancer who received radical cystectomy vs trimodality therapy.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

An artificial intelligence-based model for detecting lymph node metastases appears to identify tumor micrometastases in bladder cancer that pathologists may miss while classifying patient results as negative.

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.

Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.

Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.